24Aug 2023
Cardiovascular Disease and Chronic Obstructive Pulmonary Disease: Adding a Third Dimension to the ABE Global Initiative for Chronic Obstructive Lung Disease 2023

Cardiovascular Disease and Chronic Obstructive Pulmonary Disease: Adding a Third Dimension to the ABE Global Initiative for Chronic Obstructive Lung Disease 2023

GOLD 2023 guidelines integrate exacerbation history, symptoms, and airflow limitation for initial management. Triple therapy (LABA/LAMA/ICS) benefits symptomatic patients, especially those with cardiovascular comorbidities or risk. An ABE+ classification proposes early triple therapy for such patients, based on evidence and clinician judgment.

  • #pulmonology

Like

Save

Share